Marketresearchnews

Tuesday, 8 June 2021

Throat Lozenges Market 2020 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2027

According to MRFR, the global throat lozenges market analysis is expected to witness a moderate CAGR of 4.20% and generate a market value of USD 6.58 Billion by the end of 2023.

COVID-19 Analysis

A positive effect of the COVID-19 pandemic is expected on the Global Throat Lozenges Market. The typical signs of COVID-19 are a sore throat and coughing. Therefore, people under home confinement have been using at-home remedies for COVID-19 such as throat lozenges for chronic cough and over-the-counter pain relief for body aches. Therefore, in the next 2 to 3 years, the growing demand for throat lozenges for the treatment of initial COVID-19 symptoms of coughing and throat pain is expected to fuel the growth of the market for throat lozenges. The growing demand for throat lozenges has also led to the production of throat lozenges by companies from different industries.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1212

Throat infections are common, and lozenges are usually the first line of defence for such conditions. Throat lozenges brands continue to leverage marketing tools to increase the commercial visibility of their product. Other factors that are linked with the growth of global throat lozenges market include the development of new ingredients, rapid product penetration in fast-developing countries and low-price of throat lozenges. However, the availability of alternative treatments and therapies somewhat inhibit the market opportunities for throat lozenges.

Global Throat Lozenges Market: Segmental Analysis

MRFR’s report include a descriptive segmental analysis of the market based on type, ingredient, and indication. By type, the market has been segmented into hard-candy lozenges, soft lozenges, and compressed lozenges. The hard-candy segment is further sub-segmented into chewy or caramel based medicated tablets and centre filled hard-candy lozenges. The hard candy lozenges segment currently accounts for more than one-third share of the market and is expected to remain highly lucrative during the forecast period. In 2017, over USD 2400 Mn worth hard-candy lozenges were sold globally. By ingredient, the market has been segmented into menthol, eucalyptus oil, mint, peppermint oil, honey & ginger, lemon, and others. Among these, the menthol segment accounts for the largest market share. In 2017, the segment reached a market valuation in excess of USD 1700 Mn and projected to expand at a CAGR of 3.45% by 2023. By indication, the market has been segmented into cold and cough, sore throat, throat diseases, and others. The sore throat segment holds the pole position and the trend is likely to continue over 2023. The segment surpassed a market valuation of USD 2400 Mn in 2017.

Global Throat Lozenges Market: Regional Analysis

The report also includes a regional analysis of the market that covers Europe, North America, Asia Pacific (APAC), South America and the Middle East & Africa (MEA). Currently, North America and South America collectively account for the largest market share. In 2017, the Americas accounted for more that 31% share of the market. North America in particular is expected to remain an important market for throat lozenges during the review period. Sales of OTC medial products including throat lozenges will continue to grow in the region in the years to come. Meanwhile, Europe has emerged as the single largest market for throat lozenges. Prevalence of common cold is considerably high in various parts of Europe, which acts as favorable element for the region’s throat lozenges market.

Global Throat Lozenges Market: Competitive Landscape

Bausch Health Companies Inc, Procter & Gamble, Prestige Brands Inc, Wrigley Company, Reckitt Benkiser Group plc, Gepach International, Bliss GVS Pharma Ltd, Thornton & Ross, Ricola AG, Ernest Jackson, Mondelēz International group, GlaxoSmithKline, Pfizer Inc., Doestsch Grether AG are some of the leading companies profiled in MRFR’s report.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/throat-lozenges-market-1212

Digital Genome Market – Qualitative Insights by 2027

The global digital genome market share is expected to witness tremendous growth during the forecast period. Digital genome can be used in the diagnosis of rare diseases, genetic diseases, cancer, neurological disorders and others. The rising prevalence of chronic diseases such as breast cancer is driving the market growth. Other essential factors influencing the growth of the market are increasing geriatric population, need for efficient diagnosis and treatment, increasing number of drug discoveries, growing biotech sector, increasing research in the field of genomics and rise in funding related to digitalization. Variants of Presenilin gene lead to Alzheimer’s disease. According to Alzheimer's Association in 2018, 5.7 million people are from Alzheimer’s disease in the Americas. With the help of digital genome identifying genomic variants is easy.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1125

However, factors such as high costs of digital genome techniques, lack of knowledge about the digital genome, security issues and inaccurate results are some of the factors expected to hinder the market growth during the forecast period.

Global Digital Genome Market, by Key Players

Umbel
BiogeniQ
GenomeMe
NanoString
Illumina, Inc

Segmentation

The global digital genome market is segmented on the basis of product, application, and end-user. The global digital genome market, by product, is segmented into sequencing services, sequencing instruments, sequencing consumables, bioinformatics and sample preparation kits and reagents. The application segment is segmented into diagnostics, agriculture & animal research, personalized medicine, drug discovery and treatment analysis. On the basis of end-user, the market is categorized into research centers and government institutes, academic institutions, pharmaceutical & biotechnology industries, hospitals, and diagnostic centers. On the basis of region, the global digital genome market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.

The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.

Regional Market Summary

The digital genome market is dominated by America owing increasing prevalence of chronic diseases like cancer and diabetes. The Breastcancer.org estimated 266,120 new cases of invasive breast cancer and 63,960 new cases of non-invasive breast cancer in America in 2018. Thus, this provides favorable backgrounds for the market to grow.

It is estimated that Europe stood second in the global digital genome market. The rising demand for personalized medicine and targeted therapy is driving the growth of the market. The European Alliance for Personalized Medicine (EAPM) founded in March 2012, is involved in enhancing patient care for chronic diseases through personalized medicine. According to the European Commission in April 2018, 13 European countries have signed a declaration to share the genomic data to allow personalized treatments against cancer, rare diseases, and neurological diseases.

The digital genome market in Asia-Pacific is expected to witness growth owing to rising diabetes in this region. According to the American Diabetes Association in 2016, the Western Pacific has more than 138.2 million diabetic patients. Also, the rising healthcare spending and growing biotech sector drive the market growth in this region.

The Middle East and Africa holds the least share in the global digital genome market due to low funding in medical and health research. However, the rising prevalence of chronic diseases and increasing healthcare spending favors market growth in this region. According to the Ministry of Finance - KSA (Kingdom of Saudi Arabia) in 2018, 147 billion riyals (USD 39.2 billion) have been allocated for the Health and Social Development Sector. This enhances the market growth of digital genome in this region.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/digital-genome-market-1125

Cholesterol Management Devices Market 2020 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2027

Cholesterol is a type of lipid molecule, which is biosynthesized by all animal cells as it is an essential structural component of the cells. Cholesterol management devices are used to determine a lipoprotein profile and to measure total cholesterol content, high-density lipoprotein (HOL), low-density lipoprotein (LDL), triglycerides, and other fatty substances found in the human body. The global cholesterol management devices market is driven by increasing obese and overweight population base. According to the World Health Organization (2014), worldwide, more than 1.9 billion adults over 18 years were overweight of which over 600 million were obese. Less physical activity due to the desk-bound nature of many forms of work, changing modes of transportation, government support for the research and development, and increasing urbanization have fueled the growth of the market. However, lack of awareness among the people may slow the growth of the market.

The Global Cholesterol Management Devices Market insights Is Expected To Grow At A CAGR Of 8.5% During The Forecast Period (2017-2023).

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1045

Segmentation

The global cholesterol management devices market is segmented on the basis of types, application and end users. On the basis of types, the market is classified into monitors, wrist monitors, small portable instruments, meters, wireless systems, and others. On the basis of applications, the market is categorized into hypercholesterolemia, hypocholesterolemia, cholesterol testing, and others. On the basis of end users, the market is segmented into home based healthcare, hospitals, clinics, and others.

Regional Analysis

America continues to dominate the global cholesterol management devices market owing to the presence of a huge number of people suffering from obesity and overweight. According to the Centers for Disease Control and Prevention (2014), 73.5 million adults in the US had diagnosed with high cholesterol level. Additionally, increasing awareness among the people regarding different monitoring procedures and well-developed technology have also contributed to the growth of the market. Europe is the second largest cholesterol management devices market, which is followed by Asia Pacific. Asia Pacific is the fastest growing region for the market due to the presence of a huge patient population and continuously developing economies. On the other hand, the Middle East & Africa has the least share in the global cholesterol management devices market.

Key Players for Global Cholesterol Management Devices Market

Some of the key player in the market are Boston Scientific Corporation (US), Medtronic (US), St. Jude Medical, LLC. (Canada), Koninklijke Philips N.V. (US), Roche Diagnostics (US), Abbott (US), Alere (US), Sorin Group (Italy), BIOTRONIK SE & Co. KG (Germany), Bio-AMD (UK) and others.

The report for the global cholesterol management devices market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/cholesterol-management-devices-market-1045

CPAP Devices Market 2020 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2027

Continuous positive airway pressure (CPAP) devices are used in the treatment of choice for obstructive sleep apnea syndrome. CPAP works by blowing air into the nose and throat. The blow causes a positive pressure to hold the upper airway open during sleep and thus helps in the treatment of snoring. This device typically used when the patient has a breathing problem. Additionally, it increases the air pressure in the throat to avoid airway from collapsing when breathing. It can be used every night at home while sleeping. The global CPAP market is majorly driven by increasing number of patients with sleep apnea, obesity, and other respiratory diseases. According to the World Health Organization (WHO), in 2016, more than 1.9 billion adults, above 18 years were overweight. Out of these over 650 million were obese. The report also suggests that over 340 million children and adolescents aged 5-19 were overweight or obese in 2016. Thus, rising number of patient with obesity generating the exponential demand for CPAP devices market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/939

According to the WHO, in 2016, around 39% of 41 million children under the age of 5 were overweight or obese. Advances in technology such as improved mask design, oral appliances, use of oxygen devices, rising healthcare expenditure, and increasing demand for the devices have fuelled the market growth. However, CPAP is not always effective since some patients find it uncomfortable and sometimes it shows adverse effects. The high cost of the devices and their adverse effect may slow the market growth.

Global continuous positive airway pressure (CPAP) devices market is expected to grow at a CAGR of 7.1% during the forecast period 2017-2027.

Segmentations

Global continuous positive airway pressure (CPAP) devices market is segmented on the basis of product type, features, automation, and end user

On the basis of the product type, it is segmented into CPAP motors, CPAP hoses, CPAP mask, and others.

On the basis of the features, it is segmented into the humidifier, portability, heated tubing, and others.

On the basis of the automation, it is segmented into manual and automatic.

On the basis of the end user, it is segmented into hospitals, private clinics, home care, and others.

Regional Analysis

The Americas hold the largest share of the global market owing to increasing incidence of obesity, unhealthy diet, and physical inactivity. According to the updated report by the Centers for Disease Control and Prevention (CDC) in 2017, a total number of adults diagnosed with chronic bronchitis in the past year was 9.3 million. The report further adds that around 3.8% of the total adult population in the U.S. diagnosed with chronic bronchitis, in 2016. Presence of well-developed technology, high health care spending, increased R&D activities, and the concentration of major companies have fuelled the growth of the market in this region.

Europe holds the second position followed by the Asia Pacific in the global CPAP devices market owing to the rising patient population diagnosed with respiratory diseases. Furthermore, the government support for research & development and availability of funds for research are likely to fuel the CPAP devices market growth over the forecast period.

Asia Pacific is the fastest growing CPAP devices market owing to unhealthy diet and associated lifestyle changes. Moreover, the increased presence of rapidly developing healthcare technology, high healthcare expenditure, R&D activities, and the concentration of major companies are fuelling the growth of the market in this region. Increasing demand for new treatment methods in countries like India and South Korea is likely to emerge as the fastest growing market across the globe.

On the other hand, the Middle East and Africa account for the lowest share of the global market owing to lack of technical knowledge and poor medical facilities.

Key Players

Some of key the players in the market are Medtronic (U.S.), Koninklijke Philips N.V. (the Netherlands), 3B Medical, Inc. (U.S.), Armstrong Medical Inc. (U.S.), ResMed (U.S.), Smiths Medical (U.S.), Apex Medical Corp. (Taiwan), Fisher & Phillips LLP (U.S.), Cardinal Health (U.S.) Beijing Dehaier Medical Technology Co., Ltd. (China), DeVilbiss Healthcare LLC (US), and Invacare Corporation (US).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/continuous-positive-airway-pressure-devices-market-939

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Needle-Free Diabetes Care Market Size, Share, Demand, Financial Overview, Key Developments, Swot Analysis and Forecast to 2027

Diabetes is a group of metabolic disorders, which is caused by insulin deficiency. Needle-free is a modern technique for administration of the medication to the patient. According to the International Diabetes Federation, about 420 million adult population was suffering from diabetes in 2016, which is increasing at the rate of 8.4% per year and is expected to reach 625 million by 2040. Increasing diabetic population is the major driving factor for the growth of the market. Moreover, increasing obese population, increasing healthcare expenditure, and strong encouragement from the government have also contributed to the growth of the market. According to research, smoking increases the possibility of diabetes; more than 60% of the global population smokes, this has increased the risk of diabetes and contributed to the growth of the market. On the other hand, factors such as, lack of awareness among people and higher cost are hampering the growth of the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/912

Global needle-free diabetic care market is expected to grow at a CAGR of 7.5% during the forecast period 2017-2023.

Segmentation

The global needle-free diabetic testing market is segmented on the basis of devices types into treatment devices and diagnostic devices. Treatment devices are further segmented: insulin jet injector, insulin pen, insulin inhaler, and insulin patch & pump. Diagnostic devices are also further segmented into continuous glucose monitoring and instant glucose monitoring. On the basis of treatment, the market is segmented into oral insulin, inhaled insulin, insulin patch, and others. On the basis of applications, the market is segmented into insulin delivery and others. On the basis of end users, the market is segmented into diagnostic centers, hospitals & clinics and other.

Regional Analysis

America dominates the global needle-free diabetes care market owing to large diabetic population. Apart from this, increasing number of obese people, changing lifestyle and increasing healthcare expenditure have boosted the growth of the market in America. Europe accounts for the second largest market, which is followed by Asia Pacific. Asia Pacific is the fastest growing region in the global market due to the presence of large diabetic population.

Key Players for Global Needle-free Diabetes Care Market

Antares Pharma, Inc. (US), Bioject Medical Technologies Inc. (US), Endo International plc (US), European Pharma Group (Netherland), PharmaJet (US), Medical International Technology, Inc. (US), Valeritas, Inc. (US), PenJet Corporation (US), INJEX Pharma AG (Germany), National Medical Products Inc. (US), Crossject SA (France), Zogenix, Inc. (US), 3M Company (US).

Intended Audience

Diabetic Needle Manufacturers
Medical Research Laboratories
Academic Medical Institutes and Universities
Independent Research Laboratories
Contract Research Organizations

The report for global needle-free diabetes care market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/needle-free-diabetes-care-market-912

Gene Therapy Market 2020 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2027

According to MRFR analysis, the global gene therapy market size is expected to register a CAGR of 40.7% during the forecast period of 2019 to 2025 and was valued at USD 524 million in 2018.

Gene therapy is a technique in which a piece of DNA is incorporated into the cell via a vector. The key players are investing in the manufacturing of cell and gene therapy treatments due to its target specificity. The gene therapy is mainly of two types, somatic gene therapy, and germline gene therapy, depending on the type of cells its targets.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8399

The growth of the global gene therapy market is attributed to various factors such as robust product pipeline, increasing investment by key players, and high prevalence of target diseases and demand for innovative medication. However, the high cost of product development and stringent regulatory policies are expected to curb the growth of the global gene therapy market. The global gene therapy market is currently dominated by several market players. The key players are involved in product launches and strategic collaborations to strengthen their market positions.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the increasing prevalence of gene therapy and rising per capita healthcare expenditure. The gene therapy market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European gene therapy market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The gene therapy market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing number of patients and raising awareness about the treatment methods, the market in Asia-Pacific is expected to be the fastest-growing. The gene therapy market in the Middle East & Africa has been divided into the Middle East and Africa.

Segmentation

The global gene therapy market has been segmented based on product, indication, and end user.

The market, based on product, has been divided into kymriah, luxturna, yescarta, zolgensma, strimvelis, zynteglo, imlygic, and others.

The global gene therapy market has on the basis of indication is segmented, into oncology, genetic diseases/ disorders, and others. The oncology segment is expected to hold the largest market share and to be the fastest-growing segment due to high prevalence of cancer and robust pipeline for cancer gene therapy.

The end-user segments of the market are hospitals & clinics, specialty treatment centers, and others. The hospitals & clinics segment is expected to hold the largest market share due to increasing number of hospitals. Also, hospitals are generally the first treatment choice for diseases.

Key Players

Some of the key players in the global gene therapy market are Amgen, Inc. (US), Novartis AG (Switzerland), Spark Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), uniQure N.V. (Netherlands), Orchard Therapeutics plc (UK), Celgene Corporation (US), Bristol-Myers Squibb Company (US), Thermo Fisher Scientific Inc. (US), CEVEC (Germany), and Lonza (Switzerland).

G-Protein Coupled Receptors Market Is Seeing Explosive Growth by Future Industry Winners: Forecast, 2020-2027

According to MRFR analysis, the global G protein coupled receptors market is expected to register a CAGR of 7.1% during the forecast period of 2019 to 2025 and was valued at USD 3,100 million in 2018.

GPCRs are the largest and the most diverse group of membrane receptors in eukaryotes. They are also called transmembrane domain receptors, 7TM receptors, serpentine receptor, and G protein-linked receptors. They detect molecules outside the cell and activate internal signal transduction pathways.

The growth of global G protein coupled receptors market is driven by various factors such as growing use of G protein combined receptors in medicating disclosure and advancement forms, increasing the number of drugs under clinical and preclinical studies that target these receptors. However, the high cost involved in the maintenance of GPCR cell lines is expected to curb the growth of the global G protein coupled receptor market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8356

Several market players currently dominate the global G protein coupled receptors market. The key players are involved in product launches and strategic collaborations to strengthen their market positions.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the presence of a large number of approved drugs that target G-protein coupled receptors. The G protein coupled receptors market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European G protein coupled receptors market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The G protein coupled receptors market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The rising number of approved drugs that target GPCRs has boosted the growth of the G protein coupled receptors market, the market in Asia-Pacific is expected to be the fastest-growing. The G protein coupled receptor market in the Middle East & Africa has been divided into the Middle East and Africa.

Segmentation

The global G protein coupled receptors market has been segmented based on the product, assay type, and application.

The market, based on product, has been divided into cell lines, detection kits, cell culture reagents, ligands, and others. The detection kits segment is likely to be the fastest during the review period as they are ready to use kits that includes all cells and reagents to perform functional GPCRs assay in live cells thus driving the growth of the global G protein coupled receptor market.

The global G protein coupled receptor market has been bifurcated, on the basis of assay type, into functional calcium assays, cAMP functional assays, cGMP assays, GTP gamma S binding assays, ß-Arrestin Functional Assays, internalization assays, and others. Calcium functional assays are the fastest segment as it has numerous advantages such as user configurability, ease in the estimation of calcium flux thus driving the growth of this segment in the GPCR market.

The global G protein coupled receptors market has been segmented, based on application into the cardiovascular system, oncology, immunology, respiratory system, central nervous system, and others. The cardiovascular system is the largest segment as angiotensin II, and β-adrenergic receptors provide therapy for a wide range of cardiovascular disease such as heart failure. Approximately 17.9 million people die each year from cardiovascular disease thus rising the growth of G protein coupled receptor market.

Key Players

Some of the key players in the global G protein coupled receptor market are Thermo Fisher Scientific, Inc., Cisbio, Promega Corporation, Abcam PLC, PerkinElmer Inc., Merck Group, HD Biosciences Co., Ltd, QIAGEN, Enzo Life Sciences, and Inc.BD.